English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Mitochondrial dysfunction is observed in Parkinson’s disease (PD) and oxaloacetate (OAA), a bioenergetic pathway intermediate, was found in preclinical studies to have pro-mitochondrial effects. In this pilot study we randomized 18 PD participants to a capsule that included 100 mg OAA (in addition to 150 mg of ascorbic acid), and 15 PD participants to a capsule containing only 150 mg ascorbic acid, twice daily, for four months. Participants and study personnel were blinded to the group assignment. Thirteen participants in each group completed the study. Adverse events were recorded and clinical response was evaluated with the total Unified Parkinson’s Disease Rating Scale (UPDRS), Movement Disorder Society (MDS)-UPDRS motor and non-motor activities of daily living sections, PDQ-39 quality of life assessment, Non-Motor Symptoms Questionnaire, Montreal Cognitive Assessment, and Geriatric Depression Scale. No serious adverse events occurred and no significant differences between the groups or between the baseline and 4-month visit scores were observed for any categorical or continuous clinical assessment. In conclusion, although in this study OAA 100 mg twice daily for four months was safe in PD patients, at this dose its clinical effects were not different from placebo. Abbreviations: AD: Alzheimer’s disease; ADL: Activities of Daily Living; CBC: Complete Blood Count; CGI: Clinician Global Impression; GDS: Geriatric Depression Scale; LED: Levodopa Equivalent Dose; LFTs: Liver Function Tests; MDS: Movement Disorders Society; MoCA: Montreal Cognitive Assessment; NMSQuest: Non-Motor Symptoms Questionnaire; OAA: Oxaloacetate; PD: Parkinson’s Disease; PDQ-39; Parkinson’s Disease Questionnaire 39; PGI: Patient Global Impression; UPDRS: Unified Parkinson’s Disease Rating Scale

A Pilot Study of Oxaloacetate 100 mg Capsules in Parkinson’s Disease Patients